Evidence map›Paper›PMID 39697743›Full record

ArticleTranslational cancer research2024

Alpha-fetoprotein-to-PIVKA-II ratio as a potential biomarker for hepatocellular carcinoma differentiation, imaging characteristics, and patient survival.

Menene Nkonika Dieu-Merci, Jihong Hu, Xinyi Fang, Renjie Zhao, Xiaojie Xie, Wenqiu Pan, Thapa Aayush, Fang Yin, Hu Xingyue, Dan Han

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational cancer research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Menene Nkonika Dieu-MerciDepartment of Medical Imaging, The First Affiliated Hospital of Kunming Medical University, Kunming, China.ORCID https://orcid.org/0000-0002-5199-5648
Jihong HuDepartment of Medical Imaging, The First Affiliated Hospital of Kunming Medical University, Kunming, China.
Xinyi FangDepartment of Medical Imaging, The First Affiliated Hospital of Kunming Medical University, Kunming, China.
Renjie ZhaoDepartment of Medical Imaging, The First Affiliated Hospital of Kunming Medical University, Kunming, China.
Xiaojie XieDepartment of Medical Imaging, The First Affiliated Hospital of Kunming Medical University, Kunming, China.
Wenqiu PanDepartment of Medical Imaging, The First Affiliated Hospital of Kunming Medical University, Kunming, China.
Thapa AayushDepartment of Medical Imaging, The First Affiliated Hospital of Kunming Medical University, Kunming, China.
Fang YinDepartment of Medical Imaging, The First Affiliated Hospital of Kunming Medical University, Kunming, China.
Hu XingyueDepartment of Medical Imaging, The First Affiliated Hospital of Kunming Medical University, Kunming, China.
Dan HanDepartment of Medical Imaging, The First Affiliated Hospital of Kunming Medical University, Kunming, China.ORCID https://orcid.org/0000-0002-0408-9175

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Alpha-fetoprotein-to-PIVKA-II ratio (APR) may serve as a new marker to predict the grade of differentiation, imaging characteristics, and prognosis of hepatocellular carcinoma (HCC). This study aimed to demonstrate the prognostic significance of high APR for poorly differentiated HCC (PD-HCC), imaging characteristics and overall survival (OS) in patients after intra-arterial therapies. Methods: Receiver operating characteristic (ROC) curves were constructed and areas under the curve (AUCs) were calculated to evaluate the predictive ability of APR to discriminate subgroup(s) of HCC with good or poor prognosis. Kaplan-Meier survival analysis was performed to evaluate the effect of tumor differentiation and change in APR on overall patient survival. Results: The cut-off value of APR used in the diagnostic setting was 0.175. Almost all patients in the PD-HCC group (90.9%) had a high APR value, while 100% and 84.2% of well-differentiated and moderately differentiated HCC (WD-HCC and MD-HCC) patients, respectively, had a low APR value (P<0.001). APR had a high sensitivity (91%) and specificity (90%) in differentiating PD-HCCs from WD-HCCs/MD-HCCs (P<0.001). Patients with high APR tended to have large and multiple tumors, vascular invasion and high percentage signal ratio (PSR). OS was slightly shorter in the PD-HCC group and in the high (>0.175) APR group. Conclusions: This study showed that patients with high APR and those with PD-HCC had a worse prognosis, and APR could be an important non-invasive biomarker for predicting the degree of tumor differentiation, imaging characteristics and patient prognosis.

Indexed as

Alpha-fetoprotein-to-PIVKA-II ratio (APR)hepatocellular carcinoma (HCC)imaging characteristicsimmunohistochemical differentiationsurvival

Identifiers

PMID39697743
PMCPMC11651849

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.